Association for Relations Across the Taiwan Strait (ARATS) Chairman Chen Yunlin (陳雲林) came to Taipei for talks with Straits Exchange Foundation (SEF) Chairman Chiang Pin-kung (江丙坤) to sign an agreement on medical and health cooperation. The Department of Health (DOH) said the pact would bring standards and norms for medical products on both sides of the Taiwan Strait — including drugs, medical devices, health foods and cosmetics — into line with each other and facilitate cooperation on clinical trials for new drugs.
In other words, China and Taiwan will eventually have identical standards and norms governing medicines, and the human clinical trial stage for at least some of the drugs that find their way onto the market in Taiwan will have been carried out in China.
This news has put a smile on the faces of businesspeople on either side of the Taiwan Strait, as stocks of biotech firms shot up in value. For the rest of us, it means being extra vigilant about the safety of medicines, about the rights of people involved in clinical trials and the concomitant public health risks in the two countries.
The first issue is China’s ability to supervise and control health and medical affairs. During the SARS epidemic in 2003, the Chinese government resorted to a forced and belated mobilization of resources, a classic case of shutting the stable door after the horse had bolted. There was no consolidated epidemic prevention system in place. In 2008, in the middle of the toxic milk powder scandal, China’s food safety regulatory system was once again found sorely wanting.
Corruption in China’s drug supervision bodies has led to many drug safety incidents and scandals. In China, government departments compete with each other, and the position of Taiwan’s DOH there has always been weak. Powerful groups with vested interests often brush aside troublesome supervisory regulations, and in such cases there is little the DOH can do.
These problems are proving to be stubborn despite all the assistance the WHO has given to China to help it rebuild its health system. Put it like this: Are you going to sleep well at night knowing that new drugs appearing on the market, and in your own medicine cabinet, had their human clinical trials conducted in China, where the supervision of drugs development is in the hands of the powerful few?
The second question is Taiwan’s own record when it comes to public health. Department of Health Minister Yaung Chih-liang (楊志良), who is always mentioning how “professional” he is, denied all knowledge of the existence of a man who apparently suffered from the brain-wasting disease new variant Creutzfeldt-Jakob disease years after his return to Taiwan from the UK. That should be warning enough about the reliability of Taiwan’s public health system.
The Ministry of Economic Affairs allows the import of blood serum and plasma from China, with Yaung saying that these products are for exclusive use in external reagents and applications, and not to be used in injections.
Who is going to stand up and guarantee that? Is the health department really up to monitoring how all imported blood products are eventually used?
The third problem is that once the pact is signed, the problems with China’s health system will become Taiwan’s health risks. Even if things are done in line with international standards, who’s to say that these norms and standards are going to be thoroughly implemented in China? Let’s assume we send officials over there to carry out inspections. These will, at best, only be random checks. What about the parts not included in these random checks? DOH officials readily admit that all we can do is “hope” that their counterparts will implement adequate supervision.
Yaung and Chinese Health Minister Chen Zhu (陳竺) discussed food and drug regulation at a World Health Assembly conference in May, with Chen saying it was an opportunity that would benefit the consolidation of China’s health system.
Yaung was quite proud of this, saying that Taiwan had applied pressure on China this time round. Which is fine, but if you look at it from the other side, it tells us that the people we are dealing still have a health system they freely admit is uncoordinated.
If the WHO couldn’t get China to reform its health system, what is the likelihood that pressure exerted from Taiwan is going to do any good?
Lai Chung-chiang is a lawyer and a member of the Alliance of Supervising Cross-Strait Agreements. Wang Chan-hsi is a postdoctoral fellow.
TRANSLATED BY PAUL COOPER
Because much of what former US president Donald Trump says is unhinged and histrionic, it is tempting to dismiss all of it as bunk. Yet the potential future president has a populist knack for sounding alarums that resonate with the zeitgeist — for example, with growing anxiety about World War III and nuclear Armageddon. “We’re a failing nation,” Trump ranted during his US presidential debate against US Vice President Kamala Harris in one particularly meandering answer (the one that also recycled urban myths about immigrants eating cats). “And what, what’s going on here, you’re going to end up in World War
Earlier this month in Newsweek, President William Lai (賴清德) challenged the People’s Republic of China (PRC) to retake the territories lost to Russia in the 19th century rather than invade Taiwan. He stated: “If it is for the sake of territorial integrity, why doesn’t [the PRC] take back the lands occupied by Russia that were signed over in the treaty of Aigun?” This was a brilliant political move to finally state openly what many Chinese in both China and Taiwan have long been thinking about the lost territories in the Russian far east: The Russian far east should be “theirs.” Granted, Lai issued
On Tuesday, President William Lai (賴清德) met with a delegation from the Hoover Institution, a think tank based at Stanford University in California, to discuss strengthening US-Taiwan relations and enhancing peace and stability in the region. The delegation was led by James Ellis Jr, co-chair of the institution’s Taiwan in the Indo-Pacific Region project and former commander of the US Strategic Command. It also included former Australian minister for foreign affairs Marise Payne, influential US academics and other former policymakers. Think tank diplomacy is an important component of Taiwan’s efforts to maintain high-level dialogue with other nations with which it does
On Sept. 2, Elbridge Colby, former deputy assistant secretary of defense for strategy and force development, wrote an article for the Wall Street Journal called “The US and Taiwan Must Change Course” that defends his position that the US and Taiwan are not doing enough to deter the People’s Republic of China (PRC) from taking Taiwan. Colby is correct, of course: the US and Taiwan need to do a lot more or the PRC will invade Taiwan like Russia did against Ukraine. The US and Taiwan have failed to prepare properly to deter war. The blame must fall on politicians and policymakers